K562 erythroleukemia cells import non-transferrin-bound iron (NTBI) by an incompletely understood process that requires initial iron reduction. The mechanism of NTBI ferrireduction remains unknown but probably involves transplasma membrane electron transport. We here provide evidence for a novel mechanism of NTBI reduction and uptake by K562 cells that utilizes transplasma membrane ascorbate cycling. Incubation of cells with dehydroascorbic acid, but not ascorbate, resulted in (i) accumulation of intracellular ascorbate that was blocked by the glucose transporter inhibitor, cytochalasin B, and (ii) subsequent release of micromolar concentrations of ascorbate into the external medium via a route that was sensitive to the anion channel inhibitor, 4,4-diisothiocyanatostilbene-2,2-disulfonate. Ascorbate-deficient control cells demonstrated low levels of ferric citrate reduction. However, incubation of the cells with dehydroascorbic acid resulted in a dose-dependent stimulation of both iron reduction and uptake from radiolabeled [ 55 Fe]ferric citrate. This stimulation was abrogated by ascorbate oxidase treatment, suggesting dependence on direct chemical reduction by ascorbate. These results support a novel model of NTBI reduction and uptake by K562 cells in which uptake is preceded by reduction of iron by extracellular ascorbate, the latter of which is subsequently regenerated by transplasma membrane ascorbate cycling.Iron, the most abundant transition metal in mammalian systems, is required for normal metabolic processes spanning molecular oxygen transport, respiratory electron transfer, DNA synthesis, and drug metabolism (1). The tendency of free ferric iron to form insoluble polynuclear aggregates under physiological conditions is typically counteracted through iron sequestration by both proteinaceous and non-proteinaceous chelators in human plasma (1, 2). In addition to the cellular acquisition of iron by the classic transferrin-dependent pathway (2, 3), uptake of non-transferrin-bound iron (NTBI) 2 is well documented (4 -13). NTBI uptake may be particularly relevant in the face of iron overload diseases such as hereditary hemochromatosis, hypotransferrinemia, and thalassemia (14 -17), in which plasma iron presents in excess of transferrin-binding capacity (18). Under such conditions, NTBI uptake by tissues (e.g. liver, heart, and pancreas (16), but not brain (19)) may serve to "clear" potentially toxic levels of iron from the plasma before damage due to iron-catalyzed oxygen radicals can accumulate (5,15,20). However, such iron scavenging may also contribute to the pathophysiology of iron overload disorders (14, 16).Mechanistically, NTBI uptake depends on (i) iron reduction and (ii) consequent cellular import of ferrous iron (9, 16) by divalent metal ion transporters (e.g. divalent metal transporter, isoform 1 (21)). Although the requirement for ferrireduction in NTBI uptake is clear (9,10,22,23), the mechanism of reduction remains ill-defined. Most models propose a membrane-bound ferrireductase activity (16) i...